Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
| 适应症 | Cirrhosis, Hepatocellular Carcinoma |
|---|---|
| 分期 | 2期 |
| 申办方 | National Cancer Institute (NCI) |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 52 人 |
| 干预（药物） | Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration |
| 开始日期 | 2017年6月21日 |
| 完成日期 | 2023年5月3日 |
| 结果公布日 | 2025年4月15日 |
摘要
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Change in Serum AFP-L3%
| Group I (Simvastatin) | 0.24 ± 1.00 percent |
|---|---|
| Group II (Placebo) | -0.04 ± 0.11 percent |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)